Madrid, March 24, 2026

LABIANA HEALTH, S.A. (hereinafter, the “Company”), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with the provisions of Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, regarding information to be provided by companies listed for trading on said segment, hereby announces the following:

OTHER RELEVANT INFORMATION

Further to the “Other Relevant Information” disclosure published on March 19, 2026, regarding the outcome of the Company’s capital increase for a total cash amount of 5,072,000 euros (the “Capital Increase”) and the execution of the corresponding notarized deed, it is hereby reported that on March 20, 2026, the Capital Increase was registered in the Madrid Commercial Registry.

The necessary procedures to list the new shares resulting from the Capital Increase on BME GROWTH will be completed as soon as possible.

In compliance with the provisions of Circular 3/2020 of BME MTF Equity, it is hereby expressly stated that the information disclosed herein has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for any further clarification you may require.

Sincerely,

Mr. Manuel Ramos Ortega
Chief Executive Officer
LABIANA HEALTH, S.A.